Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Considering these changes in T2DM and the critical role of GLP-1 in glucose homeostasis, strategies for managing T2DM based on this hormone include addressing the differentiation of L-cells, increasing the endogenous production and secretion of GLP-1 through stimulants, extending the half-life of GLP-1 by inhibiting its degrading enzyme and targeting GLP-1R using its agonists
75-LB: CT-388, A novel once-weekly dual GLP-1 and GIP receptor modulator, is safe, well-tolerated, and produces more than 8% weight loss in four weeks in overweight and obese adults
ESTEL CHOCOLATIER, 10 450.00 Quick View OTIUM WINTERIA, 10 450.00 Quick View 1,810.00 - OTIUM WINTERIA, 1000 1,810.00 Quick View - OTIUM WINTERIA, 200 835.00 Quick View - ESTEL , 1000 2,050.00 Quick View - , 200 520.00 Quick View - , 200 520.00 Quick View
Other pharmacotherapies not based on entero-pancreatic hormones Several therapies that are not based on entero-pancreatic hormones are currently under evaluation for obesity and they represent further therapeutic options, considering their distinct mechanism of WL to the entero-pancreatic hormone therapies
US$ 25.66
US$ 25.96
US$ 27.53
US$ 27.11
US$ 20.02
US$ 21.62
US$ 26.10
US$ 21.76
